| Bioactivity | CypD-IN-1 is a potent and subtype-selective cyclophilin E (CypE) inhibitor. CypD-IN-1 has CypE affinity with IC50 and Ki values of 0.013 μM and 0.072 μM, respectively. CypD-IN-1 can be used for the research of several diseases including oxidative stress, neurodegenerative disorders, liver diseases, aging, autophagy and diabetes[1]. |
| Target | IC50: 0.52 μM (CypD); 1.8 μM (CypA); 5.6 μM (CypB); 0.072 μM (CypE); 0.03 μM (CypE K212A); 2 μM (CypE K217A); 0.019 μM (CypE K218A)IC50: 0.6 μM (CypD); 3 μM (CypA); 4 μM (CypB); 0.013 μM (CypE); 17 μM (CypC); 40 μM (CypG) |
| Invitro | CypD-IN-1 (C3A) has selectivity for CypD, CypA, CypB and CypE with Ki values of 0.52 μM, 1.8 μM, 5.6 μM and 0.072 μM, respectively[1].CypD-IN-1 has inhibitory activity for CypD, CypA, CypB, CypE, CypC and CypG with IC50 values of 0.6 μM, 3 μM, 4 μM, 0.013 μM, 17 μM and 40 μM, respectively[1].CypD-IN-1 has binding and inhibition potency for CypE K212A, K217A and K218A mutants with IC50 values of 0.03 μM, 2 μM and 0.019 μM, respectively[1]. |
| Name | CypE-IN-1 |
| Formula | C46H49BN6O9 |
| Molar Mass | 840.73 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Alexander A Peterson, et al. Discovery and molecular basis of subtype-selective cyclophilin inhibitors. Nat Chem Biol. 2022 Sep 26. |